###begin article-title 0
###xml 115 120 <span type="species:ncbi:9606">Human</span>
RIG-I Mediates the Co-Induction of Tumor Necrosis Factor and Type I Interferon Elicited by Myxoma Virus in Primary Human Macrophages
###end article-title 0
###begin p 1
Conceived of the project: FW GM. Performed the experiments: FW XG JB QS EB MM MR SW TI JC. Analyzed the data: FW XG JB QS EB MM MR SW TI JC GM. Wrote the paper: FW GD GM. Designed the experiments: FW XG JB QS EB MM MR SW TI JC GM.
###end p 1
###begin p 2
###xml 123 135 <span type="species:ncbi:10273">Myxoma virus</span>
###xml 137 139 <span type="species:ncbi:10273">MV</span>
###xml 199 206 <span type="species:ncbi:9986">rabbits</span>
###xml 245 247 <span type="species:ncbi:10273">MV</span>
###xml 269 274 <span type="species:ncbi:10090">mouse</span>
###xml 480 485 <span type="species:ncbi:9606">human</span>
###xml 547 549 <span type="species:ncbi:10273">MV</span>
###xml 575 580 <span type="species:ncbi:9606">human</span>
###xml 676 678 <span type="species:ncbi:10273">MV</span>
###xml 700 705 <span type="species:ncbi:9606">human</span>
###xml 905 907 <span type="species:ncbi:10273">MV</span>
###xml 1217 1222 <span type="species:ncbi:9606">human</span>
The sensing of pathogen infection and subsequent triggering of innate immunity are key to controlling zoonotic infections. Myxoma virus (MV) is a cytoplasmic DNA poxvirus that in nature infects only rabbits. Our previous studies have shown that MV infection of primary mouse cells is restricted by virus-induced type I interferon (IFN). However, little is known about the innate sensor(s) involved in activating signaling pathways leading to cellular defense responses in primary human immune cells. Here, we show that the complete restriction of MV infection in the primary human fibroblasts requires both tumor necrosis factor (TNF) and type I IFN. We also demonstrate that MV infection of primary human macrophages (pHMs) activates the cytoplasmic RNA sensor called retinoic acid inducible gene I (RIG-I), which coordinately induces the production of both TNF and type I IFN. Of note, RIG-I sensing of MV infection in pHMs initiates a sustained TNF induction through the sequential involvement of the downstream IFN-regulatory factors 3 and 7 (IRF3 and IRF7). Thus, RIG-I-mediated co-induction of TNF and type I IFN by virus-infected pHMs represents a novel innate defense mechanism to restrict viral infection in human cells. These results also reveal a new regulatory mechanism for TNF induction following viral infection.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 0 12 <span type="species:ncbi:10273">Myxoma virus</span>
###xml 113 128 <span type="species:ncbi:9986">European rabbit</span>
###xml 206 212 <span type="species:ncbi:9606">humans</span>
###xml 238 250 <span type="species:ncbi:10273">myxoma virus</span>
###xml 303 315 <span type="species:ncbi:10273">myxoma virus</span>
###xml 332 344 <span type="species:ncbi:10273">myxoma virus</span>
###xml 407 412 <span type="species:ncbi:9606">human</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 483 488 <span type="species:ncbi:9606">human</span>
###xml 521 533 <span type="species:ncbi:10273">myxoma virus</span>
###xml 668 680 <span type="species:ncbi:10273">myxoma virus</span>
###xml 692 697 <span type="species:ncbi:9606">human</span>
###xml 855 867 <span type="species:ncbi:10273">myxoma virus</span>
###xml 907 912 <span type="species:ncbi:9606">human</span>
###xml 1133 1138 <span type="species:ncbi:9606">human</span>
Myxoma virus, a member of the cytoplasmic DNA poxvirus family, causes a lethal disease called myxomatosis in the European rabbit. It has been known for over a half-century that other vertebrates, including humans, are highly resistant to myxoma virus infection, even following direct injections of live myxoma virus. Interestingly, myxoma virus has been recently shown to potently infect and kill malignant human tumors xenografted in mice. However, little is known about how normal human immune cells sense and suppress myxoma virus multiplication at the cellular level. Here, we show that the cytoplasmic RNA helicase RIG-I is the major sensor that detects invading myxoma virus in primary human macrophages and triggers the co-induction of both tumor necrosis factor and type I interferon. Together, tumor necrosis factor and type I interferon inhibit myxoma virus in otherwise permissive cells, such as human fibroblasts. Conceptually, our study thus demonstrates that intracellular RNA sensors may, in general, play a more important role than previously thought in the innate antiviral responses against DNA virus infections in human cells.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 111 114 111 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Fenner1">[1]</xref>
###xml 115 118 115 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kerr1">[2]</xref>
###xml 814 817 807 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wang1">[3]</xref>
###xml 985 988 978 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Condit1">[4]</xref>
###xml 0 12 <span type="species:ncbi:10273">Myxoma virus</span>
###xml 14 16 <span type="species:ncbi:10273">MV</span>
###xml 103 110 <span type="species:ncbi:9986">rabbits</span>
###xml 181 187 <span type="species:ncbi:9606">humans</span>
###xml 238 240 <span type="species:ncbi:10273">MV</span>
###xml 284 286 <span type="species:ncbi:10273">MV</span>
###xml 430 436 <span type="species:ncbi:9606">humans</span>
###xml 639 641 <span type="species:ncbi:10273">MV</span>
###xml 663 668 <span type="species:ncbi:10090">mouse</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
###xml 801 803 <span type="species:ncbi:10273">MV</span>
###xml 1063 1065 <span type="species:ncbi:10273">MV</span>
###xml 1094 1099 <span type="species:ncbi:9606">human</span>
Myxoma virus (MV), a member of the poxvirus family, is a large cytoplasmic DNA virus that infects only rabbits [1],[2]. No other vertebrate species outside of lagomorphs, including humans, have ever been reported to contract a productive MV infection. This strict host specificity of MV provides an important avenue to study how cross-species virus infections can be manipulated, and how zoonotic infections might be regulated in humans. For instance, the mitogen-activated protein kinase (MAPK) Erk1/2-type I interferon (IFN-alpha/beta)-STAT1 signaling cascade has been revealed as the principal antiviral defense pathway which restricts MV infection in primary mouse embryo fibroblasts. In fact, disruption of the STAT1 signaling cascade renders normally resistant mice highly susceptible to lethal MV infection [3]. These observations demonstrate the importance of defining the functional antiviral mechanisms in primary cells, as compared to transformed or immortalized cell lines [4]. Little is known, however, about the innate defense pathways that inhibit MV infection in normal primary human cells.
###end p 6
###begin p 7
###xml 258 261 258 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Akira1">[5]</xref>
###xml 262 265 262 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Janeway1">[6]</xref>
###xml 484 487 484 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kawai1">[7]</xref>
Innate cellular defenses can be triggered by a variety of mechanisms, including host recognition of pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors, such as Toll-like receptors (TLRs) and cytoplasmic nucleic acid sensors [5],[6]. Although TLR3, TLR7, TLR8 and TLR9 are known to recognize certain viral nucleic acids, these TLRs are exclusively localized in the endosomal compartments and therefore might be unable to sense cytoplasmic viral PAMPs [7].
###end p 7
###begin p 8
###xml 251 254 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Akira1">[5]</xref>
###xml 255 258 255 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Jacobs1">[8]</xref>
###xml 259 262 259 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Yoneyama1">[9]</xref>
###xml 400 403 400 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Yoneyama1">[9]</xref>
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Yoneyama2">[12]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kato1">[13]</xref>
###xml 851 855 851 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kato1">[13]</xref>
###xml 856 860 856 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Johnson1">[14]</xref>
Cellular surveillance of invading DNA viruses likely involves multiple viral PAMPs, particularly certain atypical RNAs. For example, many DNA viruses produce dsRNA and/or 5'-triphosphate RNA, as viral by-products, during their replicative life cycles [5],[8],[9]. Both viral dsRNA and 5'-triphosphate RNA can potently activate the cytoplasmic RNA sensor called retinoic acid inducible gene I (RIG-I) [9]-[12]. In contrast, certain other viral RNA moities are specifically detected by another cytoplasmic RNA sensor called melanoma differentiation-associated gene 5 (MDA5) [13]. Thus, it is highly plausible that infecting DNA viruses may generate various "accidental" RNA ligands which engage cytoplasmic RNA sensors. Current reported studies are focusing predominantly on the roles of RIG-I and MDA5 in triggering innate defenses against RNA viruses [13],[14]. Consequently, it remains to be determined how critical RIG-I and MDA5 might be in sensing DNA viruses.
###end p 8
###begin p 9
###xml 182 186 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Mogensen1">[15]</xref>
###xml 417 421 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Benedict1">[16]</xref>
###xml 422 426 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Stetson1">[18]</xref>
###xml 564 567 553 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Akira1">[5]</xref>
###xml 568 571 557 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Yoneyama1">[9]</xref>
###xml 572 576 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Hiscott1">[19]</xref>
Host recognition of viral infection normally activates multiple evolutionarily conserved signaling pathways, such as NF-kappaB and the IFN-regulatory factors 3 and 7 (IRF3 and IRF7) [15]. Activation of these pathways often culminates in the induction of an array of antiviral cytokines, including type I IFN and tumor necrosis factor (TNF), which are widely considered crucial components of innate antiviral immunity [16]-[18]. However, although the signaling cascades linking RIG-I and MDA5 sensing to IFN-alpha/beta induction have been extensively characterized [5],[9],[19], so far little is known as to how RIG-I and/or MDA5 signaling may be linked with TNF expression.
###end p 9
###begin p 10
###xml 19 21 <span type="species:ncbi:10273">MV</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 105 107 <span type="species:ncbi:10273">MV</span>
###xml 129 134 <span type="species:ncbi:9606">human</span>
###xml 205 207 <span type="species:ncbi:10273">MV</span>
###xml 229 234 <span type="species:ncbi:9606">human</span>
###xml 362 364 <span type="species:ncbi:10273">MV</span>
###xml 632 634 <span type="species:ncbi:10273">MV</span>
###xml 667 672 <span type="species:ncbi:9606">human</span>
Here, we show that MV is permissive in cultured primary human fibroblasts and that potent restriction of MV infection in primary human fibroblasts requires TNF in conjunction with type I IFN. In contrast, MV infection of primary human macrophages (pHMs) triggers induction of both TNF and type I IFN that prevents permissive infection. Furthermore, we show that MV infection of pHMs is sensed largely by RIG-I, and the subsequent TNF induction is mediated through the sequential involvement of IRF3 and IRF7. Our results demonstrate that RIG-I-mediated co-induction of TNF and IFN is a novel innate defense mechanism that restricts MV proliferation in normal primary human cells and reveals a hitherto unrecognized regulatory pathway for TNF induction in virus-infected cells.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 60 62 <span type="species:ncbi:10273">MV</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
TNF and type I IFN are required for complete restriction of MV infection in primary human fibroblasts
###end title 12
###begin p 13
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Lun1">[20]</xref>
###xml 91 95 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wu1">[22]</xref>
###xml 505 508 499 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wang1">[3]</xref>
###xml 550 559 544 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figure 1A</xref>
###xml 32 34 <span type="species:ncbi:10273">MV</span>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
###xml 130 132 <span type="species:ncbi:10273">MV</span>
###xml 163 168 <span type="species:ncbi:9606">human</span>
###xml 227 232 <span type="species:ncbi:9606">human</span>
###xml 257 259 <span type="species:ncbi:10273">MV</span>
###xml 472 474 <span type="species:ncbi:10273">MV</span>
###xml 492 498 <span type="species:ncbi:10090">murine</span>
###xml 510 512 <span type="species:ncbi:10273">MV</span>
###xml 620 622 <span type="species:ncbi:10273">MV</span>
###xml 696 701 <span type="species:ncbi:9606">human</span>
The potent oncolytic ability of MV in treating human tumors in mouse xenograft models [20]-[22] prompted our interest in studying MV infectivity in normal primary human cells. Therefore, we initially infected CCD-922Sk primary human skin fibroblasts with a MV construct expressing beta-galactosidase (beta-gal) under the control of a late viral promoter. Following low multiplicity of infection, X-gal staining revealed that, in contrast to the nonpermissive phenotype in MV-infected primary murine cells [3], MV formed classic productive blue foci (Figure 1A), indicating that CCD-922Sk fibroblasts were permissive for MV infection. Similar results were obtained with a variety of other primary human fibroblasts tested in this fashion (data not shown).
###end p 13
###begin title 14
###xml 56 58 <span type="species:ncbi:10273">MV</span>
###xml 80 85 <span type="species:ncbi:9606">human</span>
TNF and IFN-beta are required for potent restriction of MV infection in primary human fibroblasts.
###end title 14
###begin p 15
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 81 83 <span type="species:ncbi:10273">MV</span>
###xml 132 134 <span type="species:ncbi:10273">MV</span>
###xml 207 209 <span type="species:ncbi:10273">MV</span>
###xml 284 286 <span type="species:ncbi:10273">MV</span>
###xml 438 440 <span type="species:ncbi:10273">MV</span>
###xml 482 487 <span type="species:ncbi:9606">human</span>
###xml 517 519 <span type="species:ncbi:10273">MV</span>
###xml 531 536 <span type="species:ncbi:9606">human</span>
###xml 542 544 <span type="species:ncbi:10273">MV</span>
###xml 624 626 <span type="species:ncbi:10273">MV</span>
###xml 631 633 <span type="species:ncbi:10273">MV</span>
###xml 772 776 <span type="species:ncbi:12104?1.0">EMCV</span>
###xml 824 828 <span type="species:ncbi:12104?1.0">EMCV</span>
(A) Primary human skin fibroblasts CCD-922Sk were mock-infected or infected with MV. X-gal staining was performed to visualize blue MV foci 48 h after infection. (B) CCD-922Sk fibroblasts were infected with MV in the absence or presence of TNF or IFN-beta alone or TNF plus IFN-beta. MV yields were determined by the standard plaque assay using BGMK cells at 48 h after infection. (C) CCD-922Sk fibroblasts were infected with the control MV (constructed with the same vector but no human TNF gene) or the recombinant MV expressing human TNF (MV-hTNF) in the absence or presence of IFN-beta. The viral yields of both control MV and MV-hTNF were determined by the standard plaque assay using RK-13 cells at 48 h after infection. (D) CCD-922Sk fibroblasts were infected with EMCV in the absence or presence of IFN-beta or TNF. EMCV quantities were titrated by the standard plaque assay using BHK cells at 48 h after infection. Data in (B), (C) and (D) represent mean +/- SD.
###end p 15
###begin p 16
###xml 211 215 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Stetson1">[18]</xref>
###xml 216 220 213 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Samuel1">[23]</xref>
###xml 234 243 231 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figure 1B</xref>
###xml 631 635 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wong1">[24]</xref>
###xml 849 858 840 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figure 1B</xref>
###xml 1048 1057 1039 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figure 1B</xref>
###xml 1198 1207 1189 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000099.s001">Figure S1</xref>
###xml 1310 1319 1301 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figure 1C</xref>
###xml 1499 1508 1487 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figure 1C</xref>
###xml 45 47 <span type="species:ncbi:10273">MV</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 272 274 <span type="species:ncbi:10273">MV</span>
###xml 376 378 <span type="species:ncbi:10273">MV</span>
###xml 392 397 <span type="species:ncbi:9606">human</span>
###xml 451 453 <span type="species:ncbi:10273">MV</span>
###xml 689 691 <span type="species:ncbi:10273">MV</span>
###xml 801 803 <span type="species:ncbi:10273">MV</span>
###xml 886 888 <span type="species:ncbi:10273">MV</span>
###xml 1013 1015 <span type="species:ncbi:10273">MV</span>
###xml 1089 1091 <span type="species:ncbi:10273">MV</span>
###xml 1145 1147 <span type="species:ncbi:10273">MV</span>
###xml 1178 1183 <span type="species:ncbi:9606">human</span>
###xml 1189 1191 <span type="species:ncbi:10273">MV</span>
###xml 1236 1238 <span type="species:ncbi:10273">MV</span>
###xml 1240 1242 <span type="species:ncbi:10273">MV</span>
###xml 1447 1449 <span type="species:ncbi:10273">MV</span>
###xml 1564 1566 <span type="species:ncbi:10273">MV</span>
###xml 1712 1714 <span type="species:ncbi:10273">MV</span>
###xml 1742 1747 <span type="species:ncbi:9606">human</span>
###xml 1898 1900 <span type="species:ncbi:10273">MV</span>
###xml 1924 1929 <span type="species:ncbi:9606">human</span>
Next, we infected CCD-922Sk fibroblasts with MV in the presence of exogenous human IFN-beta as a prototypic representative of type I IFN to ascertain whether this cytokine could reverse the permissive phenotype [18],[23]. As shown in Figure 1B, exogenous IFN-beta reduced MV yield by approximately one log. To characterize other potential host factors that might also inhibit MV infection in human fibroblasts, we then investigated the potential anti-MV effects of other antiviral cytokines. For example, TNF has been shown to possess antiviral activities under certain circumstances, particularly in collaboration with type I IFN [24]. To this end, we infected CCD-922Sk fibroblasts with MV in the presence of TNF alone, or together with IFN-beta. We observed that approximately one log reduction in MV yield was obtained with TNF treatment alone (Figure 1B). Interestingly, this anti-MV effect of either cytokine alone was considerably enhanced when the two cytokines were combined, as that treatment inhibited MV replication by more than 4-log (Figure 1B). To further validate the anti-MV properties of TNF, we then constructed a recombinant MV that constitutively expresses human TNF (MV-hTNF, Figure S1). Compared with the control MV, MV-hTNF yield was approximately a log lower in CCD-922Sk fibroblasts (Figure 1C). Of note, this reduction could be reversed by a TNF neutralizing antibody (data not shown). Significantly, the replication of MV-hTNF was now nearly abolished by IFN-beta alone (Figure 1C). We further observed that, although the relative anti-MV potencies of TNF and type I IFN varied between individual infections, TNF in combination with either IFN-beta or IFN-alphaA uniformly restricted MV replication in all primary human cells tested (data not shown). Taken in aggregate, these data demonstrate that TNF synergizes with type I IFN to achieve potent innate restriction of MV replication in primary human fibroblasts.
###end p 16
###begin p 17
###xml 346 355 337 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figure 1D</xref>
###xml 410 419 401 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figure 1D</xref>
###xml 126 152 <span type="species:ncbi:12104">encephalomyocarditis virus</span>
###xml 154 158 <span type="species:ncbi:12104?1.0">EMCV</span>
###xml 249 251 <span type="species:ncbi:10273">MV</span>
###xml 253 257 <span type="species:ncbi:12104?1.0">EMCV</span>
###xml 395 399 <span type="species:ncbi:12104?1.0">EMCV</span>
###xml 463 467 <span type="species:ncbi:12104?1.0">EMCV</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
To further characterize the antiviral potencies of IFN-beta and TNF in CCD-922Sk fibroblasts, we then infected the cells with encephalomyocarditis virus (EMCV), an RNA virus from the picornaviridae family, in the presence of IFN-beta or TNF. Unlike MV, EMCV yield could be inhibited by more than 5-log in CCD-922Sk fibroblasts by IFN-beta alone (Figure 1D). However, TNF alone exhibited no anti-EMCV efficacy (Figure 1D), nor did it affect IFN-beta inhibition of EMCV (data not shown). Together, these results indicate that, at least in human fibroblasts, whether TNF is needed to synergize with type I IFN to achieve the full antiviral state depends significantly upon the infecting virus.
###end p 17
###begin title 18
###xml 0 2 <span type="species:ncbi:10273">MV</span>
###xml 71 76 <span type="species:ncbi:9606">human</span>
MV infection elicits robust induction of TNF and type I IFN in primary human macrophages
###end title 18
###begin p 19
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Tracey1">[25]</xref>
###xml 606 615 606 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g002">Figure 2A</xref>
###xml 689 705 689 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g001">Figures 1B and C</xref>
###xml 884 893 881 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g002">Figure 2B</xref>
###xml 1057 1066 1051 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g002">Figure 2C</xref>
###xml 53 55 <span type="species:ncbi:10273">MV</span>
###xml 163 165 <span type="species:ncbi:10273">MV</span>
###xml 352 354 <span type="species:ncbi:10273">MV</span>
###xml 500 502 <span type="species:ncbi:10273">MV</span>
###xml 542 544 <span type="species:ncbi:10273">MV</span>
###xml 587 592 <span type="species:ncbi:9606">human</span>
###xml 670 672 <span type="species:ncbi:10273">MV</span>
###xml 738 740 <span type="species:ncbi:10273">MV</span>
###xml 866 868 <span type="species:ncbi:10273">MV</span>
###xml 914 916 <span type="species:ncbi:10273">MV</span>
###xml 977 979 <span type="species:ncbi:10273">MV</span>
###xml 1018 1020 <span type="species:ncbi:10273">MV</span>
###xml 1091 1093 <span type="species:ncbi:10273">MV</span>
###xml 1327 1329 <span type="species:ncbi:10273">MV</span>
###xml 1428 1430 <span type="species:ncbi:10273">MV</span>
The involvement of TNF and type I IFN in restricting MV infection prompted us to explore macrophages as a model system to investigate the cytokine inducibility by MV infection because macrophages are generally considered as particularly potent TNF producers in response to a variety of stimuli [25]. To this end, we infected monocyte-derived pHMs with MV and then measured TNF production in response to the viral infection. A significant increase in secreted TNF protein was detected in the media of MV-infected pHMs, but not in the media of MV-infected CCD-922Sk fibroblasts or primary human lymphocytes (Figure 2A). Because type I IFN was shown to potentiate the anti-MV effects of TNF (Figures 1B and C), we therefore examined whether MV infection could also induce type I IFN expression. In accord with TNF production, IFN-beta was only detected in the media of MV-infected pHMs (Figure 2B). Next, we examined MV beta-gal activity driven by a late viral promoter following MV infection in pHMs as an indicator for MV DNA replication status. As shown in Figure 2C, only a small amount of MV beta-gal activity was detected in pHMs but this level could be increased with neutralizing antibody to either TNF or type I IFN alone, and further elevated by adding the two antibodies together. In total, these results indicate that MV-infected pHMs are restrictive because of the secreted TNF and type I IFN induced as a response to MV infection.
###end p 19
###begin title 20
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 66 68 <span type="species:ncbi:10273">MV</span>
Primary human macrophages produce TNF and IFN-beta in response to MV infection.
###end title 20
###begin p 21
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 129 131 <span type="species:ncbi:10273">MV</span>
###xml 287 289 <span type="species:ncbi:10273">MV</span>
###xml 438 440 <span type="species:ncbi:10273">MV</span>
###xml 613 615 <span type="species:ncbi:10273">MV</span>
###xml 634 636 <span type="species:ncbi:10273">MV</span>
(A, B) Primary human macrophages (pHMs), CCD-922Sk fibroblasts and primary human lymphocytes were mock-infected or infected with MV. TNF (A) and IFN-beta (B) accumulation in the culture supernatants was assessed by ELISA 24 h post-infection. (C) pHMs were mock-infected or infected with MV in the absence or presence of TNF neutralizing antibody (Ab) or IFN-alpha/beta neutralizing Ab alone or TNF Ab plus IFN-alpha/beta Ab as specified. MV beta-gal activity was determined by measuring absorbance at 420 nm and normalized to the total cellular protein levels at 48 h after infection. (D) pHMs were infected with MV or UV-inactivated MV for various times (below lanes) and total RNA was analyzed by RT-PCR for induction of TNF and IFN-beta mRNA. GAPDH was used as control. Data in (A), (B) and (C) represent mean +/- SD.
###end p 21
###begin p 22
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Falvo1">[26]</xref>
###xml 437 446 434 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g002">Figure 2D</xref>
###xml 230 232 <span type="species:ncbi:10273">MV</span>
###xml 335 337 <span type="species:ncbi:10273">MV</span>
###xml 521 523 <span type="species:ncbi:10273">MV</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
###xml 696 698 <span type="species:ncbi:10273">MV</span>
Although TNF synthesis and secretion is regulated at multiple levels, the transcriptional upregulation of TNF gene expression is a critical point of control over TNF production [26]. Therefore, we used RT-PCR to determine whether MV infection elicited the enhanced expression of TNF mRNA in pHMs. Consistent with the TNF protein data, MV infection resulted in a substantial increase in both TNF and IFN-beta mRNA, with similar kinetics (Figure 2D). No appreciable amounts of TNF or IFN-beta mRNAs were detected in either MV-infected CCD-922Sk fibroblasts or primary human lymphocytes (data not shown). Collectively, these results indicate that the co-induction of TNF and IFN-beta secretion from MV-infected pHMs was regulated through augmented mRNA transcription of each cytokine.
###end p 22
###begin p 23
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Najarro1">[27]</xref>
###xml 447 456 447 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g002">Figure 2D</xref>
###xml 614 621 611 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 27 29 <span type="species:ncbi:10273">MV</span>
###xml 130 132 <span type="species:ncbi:10273">MV</span>
###xml 267 281 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 344 346 <span type="species:ncbi:10273">MV</span>
###xml 473 475 <span type="species:ncbi:10273">MV</span>
###xml 635 637 <span type="species:ncbi:10273">MV</span>
Next, to determine whether MV replication was required to induce TNF or type I IFN expression in pHMs, we prepared UV-inactivated MV that was no longer able to synthesize significant levels of functional viral RNA or protein in a fashion similar to that reported for vaccinia virus [27]. Radioiodination labeling showed that the UV-inactivated MV particles retained the ability to enter into the cell interior (data not shown). As demonstrated in Figure 2D, UV-inactivated MV was unable to upregulate mRNA expression of either TNF (3rd panel) or IFN-beta (4th panel) in pHMs. Together, these data suggest that the de novo synthesis of MV macromolecules is critical for triggering the cellular signaling cascades leading to TNF and IFN-beta induction in pHMs.
###end p 23
###begin title 24
###xml 15 17 <span type="species:ncbi:10273">MV</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
RIG-I mediates MV-elicited induction of TNF and type I IFN in primary human macrophages
###end title 24
###begin p 25
###xml 102 105 102 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kerr1">[2]</xref>
###xml 212 221 209 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g002">Figure 2D</xref>
###xml 291 295 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Yoneyama2">[12]</xref>
###xml 296 300 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kato1">[13]</xref>
###xml 575 584 572 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3A</xref>
###xml 897 901 894 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Nakamichi1">[28]</xref>
###xml 902 906 899 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Okazawa1">[29]</xref>
###xml 1027 1036 1024 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3A</xref>
###xml 1053 1062 1050 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3A</xref>
###xml 1208 1217 1205 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3B</xref>
###xml 1384 1393 1381 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3B</xref>
###xml 21 23 <span type="species:ncbi:10273">MV</span>
###xml 130 132 <span type="species:ncbi:10273">MV</span>
###xml 198 200 <span type="species:ncbi:10273">MV</span>
###xml 366 368 <span type="species:ncbi:10273">MV</span>
###xml 647 649 <span type="species:ncbi:10273">MV</span>
###xml 1091 1093 <span type="species:ncbi:10273">MV</span>
###xml 1249 1251 <span type="species:ncbi:10273">MV</span>
###xml 1366 1368 <span type="species:ncbi:10273">MV</span>
Like all poxviruses, MV synthesizes its viral DNA, RNA and protein in the cytoplasm of infected cells [2]. Thus, the finding that MV-elicited TNF and IFN-beta mRNA induction in pHMs required active MV infection (Figure 2D) led us to postulate that cytoplasmic sensors, such as RIG-I or MDA5 [12],[13], might sense cytoplasmic nucleic acid intermediates derived from MV replication. To test this hypothesis, we examined the basal levels of RIG-I and MDA5 in pHMs. As revealed by RT-PCR, mRNAs for the nucleic acid sensors RIG-I and MDA5 were constitutively expressed in pHMs (Figure 3A). Next, to investigate whether these sensors were involved in MV-elicited TNF or IFN induction, we employed siRNAs to individually suppress the expression of RIG-I and MDA5 in pHMs, as previous reports have shown that siRNA transfection could efficiently inhibit a variety of target genes in primary macrophages [28],[29]. We observed that transfection of RIG-I siRNA-1 and MDA5 siRNA significantly knocked down the mRNA expression of RIG-I (Figure 3A, top) and MDA5 (Figure 3A, middle). We then conducted MV infections in the pHMs in which the expression of RIG-I and MDA5 mRNA had been respectively silenced. As shown in Figure 3B, MDA5 mRNA suppression reduced MV-elicited TNF production only by approximately 30%, whereas RIG-I mRNA knockdown inhibited TNF induction by 85% in MV-infected pHMs (Figure 3B).
###end p 25
###begin title 26
###xml 0 2 <span type="species:ncbi:10273">MV</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
MV-elicited production of TNF and IFN-beta is mediated by RIG-I in primary human macrophages.
###end title 26
###begin p 27
###xml 274 276 <span type="species:ncbi:10273">MV</span>
###xml 402 404 <span type="species:ncbi:10273">MV</span>
###xml 560 562 <span type="species:ncbi:10273">MV</span>
###xml 656 658 <span type="species:ncbi:10273">MV</span>
###xml 660 662 <span type="species:ncbi:10273">MV</span>
(A) pHMs were transfected with control siRNA or siRNAs targeting cytoplasmic RNA sensors RIG-I (top panel) or MDA5 (middle panel). The cells were analyzed 48 h later by RT-PCR for the indicated mRNA levels. GAPDH was used as control. (B, C) RIG-I is critically required for MV-elicited production of both TNF (B) and IFN-beta (C) in pHMs. pHMs or various siRNA pHMs were mock-infected or infected with MV and the accumulation of TNF and IFN-beta in the culture supernatants was assessed by ELISA 24 h post-infection. (D) RIG-I mediates cellular restriction to MV infection in pHMs. pHMs or control siRNA or RIG-I siRNA pHMs as indicated were infected with MV. MV yields were determined by the standard plaque assay using BGMK cells at 48 h after infection. Data in (B), (C) and (D) represent mean +/- SD.
###end p 27
###begin p 28
###xml 71 79 68 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g002">Figure 2</xref>
###xml 186 195 180 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3C</xref>
###xml 384 393 375 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3D</xref>
###xml 53 55 <span type="species:ncbi:10273">MV</span>
###xml 107 109 <span type="species:ncbi:10273">MV</span>
###xml 350 352 <span type="species:ncbi:10273">MV</span>
###xml 409 411 <span type="species:ncbi:10273">MV</span>
###xml 540 542 <span type="species:ncbi:10273">MV</span>
###xml 695 697 <span type="species:ncbi:10273">MV</span>
Because IFN-beta was co-induced together with TNF in MV-infected pHMs (Figure 2), we then examined whether MV-elicited IFN-beta expression was also mediated by RIG-I. As demonstrated in Figure 3C, RIG-I silencing reduced IFN-beta production comparably to that of TNF. Importantly, virus yield analysis further revealed that RIG-I knockdown increased MV progeny production by 30-fold (Figure 3D) and augmented MV-derived beta-gal activity by 80% (data not shown). Taken together, these data suggest that RIG-I is a major common mediator for MV-elicited induction of TNF and type I IFN in infected pHMs and that knockdown of RIG-I reduces this co-induction and thereby renders pHMs permissive for MV infection.
###end p 28
###begin p 29
###xml 128 138 128 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000099.s002">Figure S2A</xref>
###xml 389 408 386 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000099.s002">Figures S2B and S2C</xref>
###xml 758 777 755 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000099.s003">Figures S3A and S3B</xref>
###xml 779 783 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Reynolds1">[30]</xref>
###xml 784 788 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Sledz1">[31]</xref>
###xml 291 293 <span type="species:ncbi:10273">MV</span>
###xml 591 593 <span type="species:ncbi:10273">MV</span>
To verify the specificity of RIG-I siRNA silencing, we employed an additional RIG-I siRNA designated RIG-I siRNA-2. As shown in Figure S2A, RIG-I siRNA-2 displayed a silencing potency indistinguishable from that of RIG-I siRNA-1. Phenotypically, RIG-I silencing by RIG-I siRNA-2 reduced the MV-induced expressions of both TNF and IFN-beta to the similar levels as seen with RIG-I siRNA-1 (Figures S2B and S2C). Because the sequences of RIG-I siRNA-1 and RIG-I siRNA-2 are different, it is thus unlikely that these siRNA oligos both knockdown a common off-target gene that is responsible for MV-elicited expression of TNF and type I IFN. Moreover, we also observed that RIG-I siRNAs used here themselves did not trigger undesired type I IFN response in pHMs (Figures S3A and S3B) [30],[31].
###end p 29
###begin p 30
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kawai1">[7]</xref>
###xml 51 53 <span type="species:ncbi:10273">MV</span>
###xml 435 437 <span type="species:ncbi:10273">MV</span>
Next, to examine for any potential role of TLRs in MV-infected pHMs, we silenced the expressions of TLR4, MyD88 and Trif using specific siRNAs. These were chosen because all known TLRs use either the adaptor MyD88 or Trif to transduce signals, except for TLR4, which uses both adaptors MyD88 and Trif [7]. We observed that inhibition of TLR signaling with any of these siRNAs had no influence on either TNF or type I IFN production in MV-infected pHMs (data not shown).
###end p 30
###begin title 31
###xml 80 85 <span type="species:ncbi:9606">human</span>
IRF3 is essential for RIG-I-mediated induction of TNF and type I IFN in primary human macrophages
###end title 31
###begin p 32
###xml 64 68 64 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Seth1">[32]</xref>
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kawai2">[33]</xref>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Xu1">[35]</xref>
###xml 251 255 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Honda1">[36]</xref>
###xml 256 260 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Sato1">[37]</xref>
###xml 349 353 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Covert1">[38]</xref>
###xml 354 358 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Nociari1">[41]</xref>
###xml 567 576 560 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4A</xref>
###xml 759 768 752 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4B</xref>
###xml 839 843 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Honda1">[36]</xref>
###xml 932 941 925 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4B</xref>
###xml 963 972 956 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4B</xref>
###xml 1084 1093 1077 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4C</xref>
###xml 493 495 <span type="species:ncbi:10273">MV</span>
###xml 782 784 <span type="species:ncbi:10273">MV</span>
###xml 1070 1072 <span type="species:ncbi:10273">MV</span>
###xml 1130 1132 <span type="species:ncbi:10273">MV</span>
Upon ligand engagement, RIG-I recruits the adaptor protein MAVS [32], also known as VISA, IPS-1 or Cardif [33]-[35], resulting in the downstream activation and nuclear localization of IRF3, a central transcription factor for IFN-alpha/beta expression [36],[37]. Importantly, recent studies demonstrate that IRF3 is also important for TNF expression [38]-[41]. To investigate whether signaling from MAVS to IRF3 is critically involved in RIG-I-mediated induction of TNF or type I IFN following MV infection, we first silenced MAVS expression in pHMs using MAVS siRNA (Figure 4A). We then prepared pHM nuclear extracts and examined, by immunoblotting, IRF3 nuclear translocation with or without MAVS silencing in comparison with RIG-I silencing. As revealed in Figure 4B (top panel), MV infection robustly induced IRF3 nuclear translocation [36]. This nuclear mobilization of IRF3 was strongly inhibited by knockdown of either RIG-I (Figure 4B, 2nd panel) or MAVS (Figure 4B, 3rd panel). Immunofluorescent staining revealed a similar distribution trend for IRF3 following MV infection (Figure 4C). Together, these results show that MV-induced IRF3 activation is dependent on the functional integrity of upstream signaling of both RIG-I and MAVS.
###end p 32
###begin title 33
###xml 32 34 <span type="species:ncbi:10273">MV</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
IRF3 is critical for triggering MV-elicited TNF induction in primary human macrophages.
###end title 33
###begin p 34
###xml 256 258 <span type="species:ncbi:10273">MV</span>
###xml 515 517 <span type="species:ncbi:10273">MV</span>
###xml 894 896 <span type="species:ncbi:10273">MV</span>
###xml 1062 1064 <span type="species:ncbi:10273">MV</span>
(A) pHMs were transfected with control siRNA or MAVS siRNA. The cells were analyzed 48 h later by RT-PCR for the indicated mRNA levels. GAPDH was used as the control. (B) Control siRNA pHMs or RIG-I siRNA or MAVS siRNA pHMs as indicated were infected with MV for various times (below lanes) and the nuclear extracts were probed for nuclear IRF3 (nuc-IRF3). Nuclear USF2 (nuc-USF2) was used as nuclear protein loading control. (C) Control siRNA pHMs or RIG-I siRNA or MAVS siRNA pHMs as indicated were infected with MV for 0 h or 10 h and were immunofluorescence-stained for IRF3 (red). Nuclear DNA was counterstained with DAPI (blue). Bars are 10 microm. (D) pHMs were transfected with control siRNA or IRF3 siRNA as indicated and were analyzed 72 h later by immunoblotting for IRF3 protein levels. beta-actin was used as control. (E) pHMs or various siRNA pHMs as indicated were infected with MV for 24 h and TNF protein in the culture supernatants was assessed by ELISA. Data represent mean +/- SD. (F) Control siRNA pHMs or IRF3 siRNA pHMs were infected with MV for various times (below lanes) and the cells were analyzed by RT-PCR for the indicated TNF mRNA levels. GAPDH was used as control.
###end p 34
###begin p 35
###xml 152 161 152 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4D</xref>
###xml 271 280 271 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4E</xref>
###xml 369 378 369 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4E</xref>
###xml 629 638 626 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4F</xref>
###xml 49 51 <span type="species:ncbi:10273">MV</span>
###xml 253 255 <span type="species:ncbi:10273">MV</span>
###xml 333 335 <span type="species:ncbi:10273">MV</span>
###xml 463 465 <span type="species:ncbi:10273">MV</span>
###xml 556 558 <span type="species:ncbi:10273">MV</span>
To investigate the physiological significance of MV-induced IRF3 activation in pHMs, we employed IRF3 siRNA to specifically knock down IRF3 expression (Figure 4D). This knockdown of IRF3 substantially reduced TNF protein secretion in the supernatant of MV-infected pHMs (Figure 4E). Similarly, MAVS silencing also strongly inhibited MV-elicited TNF production in pHMs (Figure 4E). These results suggest that MAVS-IRF3 signaling is important for TNF production in MV-infected pHMs. Consistent with these TNF protein data, we also observed that induction of MV-elicited TNF and IFN-beta mRNA were both inhibited by IRF3 silencing (Figure 4F and data not shown), thus indicating that IRF3 regulates TNF and IFN-beta production mainly through transcriptional activation. Taken together, our findings suggest that the RIG-I-MAVS-IRF3 signaling axis, a canonical cascade that is involved in IFN-alpha/beta induction following RNA virus infections, can also be exploited in pHMs to co-transmit TNF-inducing signals emanating from a cytoplasmic DNA virus infection.
###end p 35
###begin title 36
###xml 72 77 <span type="species:ncbi:9606">human</span>
IRF7 is required for sustaining RIG-I-mediated TNF induction in primary human macrophages
###end title 36
###begin p 37
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Honda1">[36]</xref>
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Servant1">[42]</xref>
###xml 400 409 400 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g005">Figure 5A</xref>
###xml 700 709 700 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g005">Figure 5A</xref>
###xml 933 942 933 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g005">Figure 5B</xref>
###xml 1270 1279 1270 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g005">Figure 5C</xref>
###xml 179 181 <span type="species:ncbi:10273">MV</span>
###xml 251 253 <span type="species:ncbi:10273">MV</span>
###xml 386 388 <span type="species:ncbi:10273">MV</span>
###xml 421 423 <span type="species:ncbi:10273">MV</span>
###xml 644 646 <span type="species:ncbi:10273">MV</span>
###xml 819 821 <span type="species:ncbi:10273">MV</span>
###xml 856 858 <span type="species:ncbi:10273">MV</span>
###xml 987 989 <span type="species:ncbi:10273">MV</span>
###xml 1142 1144 <span type="species:ncbi:10273">MV</span>
IRF7 shares considerable structural and functional similarities with IRF3 [36],[42]; therefore, we investigated whether IRF7 also played a role in RIG-I-mediated TNF induction in MV-infected pHMs. To this end, we first analyzed IRF7 protein levels in MV-infected pHMs by immunoblotting. We found that IRF7 protein was not detectable in uninfected pHMs, but was significantly induced by MV infection (Figure 5A). Notably, MV-induced IRF7 expression in pHMs became markedly augmented at 12-16 h after infection and remained elevated even at 24 h post-infection. To determine whether IRF7 was involved in RIG-I-mediated TNF induction, we silenced MV-induced expression of IRF7 in pHMs using IRF7 siRNA (Figure 5A, middle panel). Next, we measured TNF secretion in the media of control and IRF7-silenced pHMs at 24 h after MV infection. IRF7 silencing reduced MV-elicited TNF production, but to a lesser degree than with IRF3 silencing (Figure 5B). Subsequently, we compared the kinetics of MV-elicited TNF production in pHMs. Initially, the amounts of TNF protein secreted by control and IRF7-silenced pHMs were similar during the first 12 h of MV infection. However, further increases in TNF protein were significantly impaired in IRF7-silenced pHMs at later time points (Figure 5C).
###end p 37
###begin title 38
###xml 31 33 <span type="species:ncbi:10273">MV</span>
###xml 68 73 <span type="species:ncbi:9606">human</span>
IRF7 is crucial for sustaining MV-elicited TNF induction in primary human macrophages.
###end title 38
###begin p 39
###xml 61 63 <span type="species:ncbi:10273">MV</span>
###xml 141 143 <span type="species:ncbi:10273">MV</span>
###xml 279 281 <span type="species:ncbi:10273">MV</span>
###xml 472 474 <span type="species:ncbi:10273">MV</span>
###xml 645 647 <span type="species:ncbi:10273">MV</span>
###xml 716 718 <span type="species:ncbi:10273">MV</span>
(A) Control siRNA pHMs or IRF7 siRNA pHMs were infected with MV for various times (below lanes) and the whole cell lysates were analyzed for MV-induced expression of IRF7 protein. beta-actin was used as control. (B) pHMs or various siRNA pHMs were mock-infected or infected with MV. TNF protein in the culture supernatants was assessed by ELISA 24 h post-infection. (C) IRF7 expression and TNF production kinetics. Control siRNA pHMs or IRF7 siRNA pHMs were infected with MV for various times as indicated and TNF protein in the culture supernatants was assessed by ELISA. (D) IRF7 is required for sustaining TNF gene transcription activated by MV infection. Control siRNA pHMs or IRF7 siRNA pHMs were infected with MV for various times (below lanes) and the cells were analyzed by RT-PCR for the indicated TNF mRNA levels. GAPDH was used as control. Data in (B) and (C) represent mean +/- SD.
###end p 39
###begin p 40
###xml 327 336 327 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g005">Figure 5D</xref>
###xml 445 454 445 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g005">Figure 5D</xref>
###xml 512 521 512 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g005">Figure 5C</xref>
###xml 44 46 <span type="species:ncbi:10273">MV</span>
###xml 207 209 <span type="species:ncbi:10273">MV</span>
###xml 431 433 <span type="species:ncbi:10273">MV</span>
###xml 709 711 <span type="species:ncbi:10273">MV</span>
In order to ascertain whether IRF7 affected MV-elicited TNF induction at the transcriptional or post-transcriptional level, we analyzed TNF mRNA in both control and IRF7-silenced pHMs after various times of MV infection. As revealed by RT-PCR, TNF mRNA was induced to similar levels in both groups at the early times (8-12 h) (Figure 5D). In contrast, much less TNF mRNA was detected at the later times in IRF7-silenced pHMs after MV infection (Figure 5D). These results are congruent with the TNF protein data (Figure 5C) and suggest that IRF3 is responsible for the initial triggering of TNF induction while IRF7 impacts the secondary amplification of TNF expression by sustaining TNF gene transcription in MV-infected pHMs.
###end p 40
###begin p 41
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Ning1">[43]</xref>
###xml 654 663 654 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g005">Figure 5A</xref>
###xml 828 837 828 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figure 6A</xref>
###xml 865 874 865 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figure 6B</xref>
###xml 1069 1073 1065 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Honda1">[36]</xref>
###xml 1074 1078 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Lu1">[44]</xref>
###xml 1079 1083 1075 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Marie1">[45]</xref>
###xml 1130 1139 1122 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figure 6C</xref>
###xml 1158 1167 1150 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figure 6C</xref>
###xml 1355 1371 1343 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figures 6A and B</xref>
###xml 1395 1411 1383 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figures 6A and B</xref>
###xml 1632 1636 1620 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Honda1">[36]</xref>
###xml 2131 2147 2111 2127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figures 6A and B</xref>
###xml 2170 2186 2150 2166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figures 6A and B</xref>
###xml 2229 2238 2209 2218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3A</xref>
###xml 2243 2252 2223 2232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g004">Figure 4A</xref>
###xml 2316 2325 2296 2305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g003">Figure 3A</xref>
###xml 2363 2379 2343 2359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000099-g006">Figures 6A and B</xref>
###xml 41 43 <span type="species:ncbi:10273">MV</span>
###xml 146 148 <span type="species:ncbi:10273">MV</span>
###xml 490 492 <span type="species:ncbi:10273">MV</span>
###xml 918 920 <span type="species:ncbi:10273">MV</span>
###xml 1920 1922 <span type="species:ncbi:10273">MV</span>
###xml 2496 2498 <span type="species:ncbi:10273">MV</span>
###xml 2651 2653 <span type="species:ncbi:10273">MV</span>
The prominent role of IRF7 in sustaining MV-elicited later stage TNF production piqued our interest in the primary regulatory pathway involved in MV-induced IRF7 expression. In this regard, previous work shows that virus-activated IRF3 and IRF7 can bind to the IFN-stimulated response element (ISRE) and IRF-binding element (IRFE) in the endogenous IRF7 promoter to initiate IRF7 transcription [43]. Therefore, we performed a chromatin immunoprecipitation (ChIP) assay to determine whether MV infection of pHMs induced IRF3 and IRF7 binding to the IRF7 ISRE and IRFE at 12 h after infection, as IRF7 first became markedly upregulated at this time point (Figure 5A, top panel). We observed that the PCR-amplified DNA bands diagnostic for the ISRE and IRFE elements in the endogenous IRF7 promoter were detected in the anti-IRF3 (Figure 6A, top panel) and anti-IRF7 (Figure 6B, top panel) antibody immunoprecipitates of MV-infected pHMs, but not in the control antibody immunoprecipitates. Because TNF-NF-kappaB and IFN-STAT1 pathways are known to activate the IRF7 gene [36],[44],[45], we silenced the expression of NF-kappaB p65 (Figure 6C, left) and STAT1 (Figure 6C, right) to ascertain whether these signaling cascades had any impact on the observed IRF3 and IRF7 binding. Notably, the specific DNA bands were unaffected by silencing of NF-kappaB p65 (Figures 6A and B, 5th panels) or STAT1 (Figures 6A and B, 6th panels). In particular, STAT1 forms a heterotrimeric complex called ISGF3 (IFN-stimulated gene factor 3) with STAT2 and IRF9 following the activation by type I IFN and is a major stimulator for IRF7 gene expression [36]. Thus, to further define the STAT1 silencing effects, we observed that no positive ChIP signals were detected for IRF7 gene promoter in STAT1 siRNA pHMs following IFN-alphaA treatment (data not shown). These results together indicate that NF-kappaB p65 and STAT1 are not involved in MV-induced direct binding of IRF3 and IRF7 to the endogenous IRF7 promoter. Significantly, no specific DNA bands diagnostic for the IRF7 ISRE/IRFE promoter elements were detectable when the expression of RIG-I (Figures 6A and B, 2nd panels) or MAVS (Figures 6A and B, 4th panels) was knocked down as shown in Figure 3A and Figure 4A, respectively. In contrast, when MDA5 was silenced as shown in Figure 3A, ChIP retained the positive signals (Figures 6A and B, 3rd panels). This result is congruent with the findings that MDA5 silencing itself had little inhibitory impact on MV-induced activation of IRF3 and IRF7 (data not shown). Taken collectively, these data suggest that both IRF3 and IRF7 are directly involved in promoting MV-triggered IRF7 gene transcription through RIG-I and MAVS, but independently of type I IFN and NF-kappaB signaling.
###end p 41
###begin title 42
###xml 0 2 <span type="species:ncbi:10273">MV</span>
###xml 76 81 <span type="species:ncbi:9606">human</span>
MV induces IRF3 and IRF7 binding to the endogenous IRF7 promoter in primary human macrophages.
###end title 42
###begin p 43
###xml 197 199 <span type="species:ncbi:10273">MV</span>
(A, B) Chromatin immunoprecipitation assay. IRF3 and IRF7 binding to the ISRE and IRFE in the endogenous IRF7 promoter was determined in control siRNA pHMs or various siRNA pHMs as indicated after MV infection for 12 h using PCR to detect IRF7 ISRE and IRFE in immunoprecipitated chromatin fragments. Lanes 1 and 2 are the PCR results for immunoprecipitated samples with the control antibody (Ab). Lanes 3 and 4 show PCR amplification of target sequences in immunoprecipitated chromatin fragments with anti-IRF3 (A) or anti-IRF7 (B) antibody. Input represents PCR amplification of the total input DNA in each sample from the corresponding treatment. (C) pHMs were transfected with control siRNA or specific siRNAs as indicated. The cells were analyzed 72 h later by immunoblotting for protein levels of NF-kappaB p65 (left) and STAT1 (right). beta-actin was used as control.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Covert1">[38]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Nociari1">[41]</xref>
###xml 206 208 <span type="species:ncbi:10273">MV</span>
###xml 792 797 <span type="species:ncbi:9606">human</span>
Deciphering the cellular sensing mechanisms involved in virus-elicited TNF or IFN induction is key for understanding the biology of these cytokines in innate antiviral defenses. In this study, we show that MV infection of pHMs triggers the cytoplasmic RNA sensor RIG-I, which activates a MAVS-IRF3/IRF7 cascade leading to the co-induction of TNF and type I IFN. Although IRF3 has been shown to mediate TNF induction under various circumstances, such as lipopolysaccharide stimulation or certain viral infections [38]-[41], the collaboration between IRF3 and IRF7 resulting in sustained TNF induction has not been recognized before. Thus, our study has revealed novel insights into the signaling control of TNF production, and its close linkage with type I IFN upregulations in virus-infected human macrophages.
###end p 45
###begin p 46
###xml 377 381 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kumar1">[46]</xref>
###xml 575 579 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Cheng1">[47]</xref>
###xml 861 864 855 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Yoneyama1">[9]</xref>
###xml 937 941 931 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kato1">[13]</xref>
###xml 1112 1116 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Gitlin1">[48]</xref>
###xml 300 305 <span type="species:ncbi:10090">mouse</span>
###xml 510 515 <span type="species:ncbi:9606">human</span>
###xml 623 625 <span type="species:ncbi:10273">MV</span>
###xml 744 746 <span type="species:ncbi:10273">MV</span>
The first indication of potential involvement of the cytoplasmic RNA helicases in sensing DNA virus infection came from the knockdown of MAVS (also called IPS-1), the sole known adaptor for RIG-I and MDA5 signaling, in which IFN-beta induction was shown to be substantially reduced in MAVS-deficient mouse embryo fibroblasts following the infection by modified vaccinia Ankara [46]. More recently, DNA viruses herpes simplex virus-1 and adenovirus were shown to replicate to much higher titers in RIG-I mutant human hepatoma cells Huh-7.5.1. than in the parental Huh-7 cells [47]. The critical function of RIG-I in sensing MV infection of pHMs raises an interesting question about why MDA5 has an apparently less significant role in triggering MV-elicited induction of TNF and IFN-beta. Although RIG-I and MDA5 belong to the same family of DexD/H box helicases [9], MDA5 is known to preferentially recognize picornaviruses and poly(I:C) [13]. Thus far, MDA5 deficiency has been shown to have either no effect, or only a slight inhibitory impact, on the type I IFN responses elicited by other RNA and DNA viruses [48]. Taken together with these previous studies, our data thus point to an emerging theme that RIG-I may play a more general role in innate recognition of various DNA viruses.
###end p 46
###begin p 47
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Takaoka1">[49]</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wang2">[50]</xref>
###xml 385 390 <span type="species:ncbi:10090">mouse</span>
###xml 665 667 <span type="species:ncbi:10273">MV</span>
This is of importance considering the fact that information remains limited about the cytoplasmic DNA sensor(s). Presently, the only characterized cytoplasmic DNA sensor DAI, also known as DLM-1/ZBP1, was shown to mediate type I IFN induction following infection with herpes simplex virus-1 in L929 cells [49]. However, sensing of cytoplasmic DNA by DAI was found to be dispensable in mouse embryo fibroblasts [50]. Thus, it appears that the role of DAI in DNA sensing may be a cell type specific or functional status-related phenomenon. In the present study, we observed that DAI knockdown inflicted only a minor inhibitory effect on TNF and IFN-beta induction in MV-infected pHMs (data not shown). This result seems to further emphasize the importance of RIG-I as an innate sensor for DNA virus infections.
###end p 47
###begin p 48
###xml 307 310 307 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wang1">[3]</xref>
###xml 687 691 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Johnston1">[51]</xref>
###xml 22 24 <span type="species:ncbi:10273">MV</span>
###xml 57 59 <span type="species:ncbi:10273">MV</span>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
###xml 138 140 <span type="species:ncbi:10273">MV</span>
###xml 283 285 <span type="species:ncbi:10273">MV</span>
###xml 289 294 <span type="species:ncbi:10090">mouse</span>
###xml 352 357 <span type="species:ncbi:9606">human</span>
###xml 459 461 <span type="species:ncbi:10273">MV</span>
###xml 659 661 <span type="species:ncbi:10273">MV</span>
###xml 878 880 <span type="species:ncbi:10273">MV</span>
###xml 984 986 <span type="species:ncbi:10273">MV</span>
###xml 1134 1136 <span type="species:ncbi:10273">MV</span>
###xml 1180 1185 <span type="species:ncbi:9606">human</span>
Our previous study of MV tropism restriction showed that MV infection not only induced type I IFN in primary mouse embryo fibroblasts but MV replication was exquisitely sensitive to the induced IFN, demonstrating that the type I IFN response is a predominant tropism determinant for MV in mouse fibroblasts [3]. Of note, a previous study using primary human neonatal foreskin fibroblasts reported that the early passage (P1-3) fibroblasts were permissive for MV infection, while late passage cells (P5-10) became resistant at a time that paralleled the acquisition of constitutive IFN-beta secretion, thus indicating a major role for type I IFN in inhibiting MV infection in those cells [51]. In the present study, however, we found that adult breast skin fibroblasts (CCD-922Sk), adult abdomen skin, fetal lung and fetal conjunctival fibroblasts uniformly supported permissive MV infection, regardless of the passage status, and all required both TNF and type I IFN to fully inhibit MV proliferation (data not shown). Taken together, these findings suggest that both TNF and type I IFN are necessary for a full-fledged inhibition of MV infection in a wide variety of the primary human fibroblasts tested although type I IFN itself might still be able to act as a potent inhibitor in certain cells.
###end p 48
###begin p 49
###xml 25 27 <span type="species:ncbi:10273">MV</span>
###xml 203 205 <span type="species:ncbi:10273">MV</span>
###xml 413 415 <span type="species:ncbi:10273">MV</span>
###xml 499 501 <span type="species:ncbi:10273">MV</span>
###xml 522 527 <span type="species:ncbi:9606">human</span>
We also report here that MV infection co-induced TNF and type I IFN only in pHMs, but not in primary fibroblasts or lymphocytes, in a RIG-I-dependent fashion. Hence, these data imply either that certain MV gene products act as RIG-I signaling pathway inhibitor(s) only in fibroblasts and lymphocytes or else there exist unique signaling elements of the RIG-I pathway that are restricted to pHMs. In either event, MV immunosubversion effectors may well be inherently involved in the determination of MV tropisms in primary human cells in a cell type-dependent manner.
###end p 49
###begin p 50
###xml 491 494 491 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Fenner1">[1]</xref>
###xml 793 800 793 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 56 58 <span type="species:ncbi:10273">MV</span>
###xml 95 97 <span type="species:ncbi:10273">MV</span>
###xml 153 155 <span type="species:ncbi:10273">MV</span>
###xml 284 286 <span type="species:ncbi:10273">MV</span>
###xml 402 408 <span type="species:ncbi:9606">humans</span>
###xml 433 435 <span type="species:ncbi:10273">MV</span>
###xml 488 490 <span type="species:ncbi:10273">MV</span>
###xml 566 568 <span type="species:ncbi:10273">MV</span>
###xml 582 588 <span type="species:ncbi:9606">humans</span>
###xml 750 752 <span type="species:ncbi:10273">MV</span>
###xml 786 792 <span type="species:ncbi:9606">humans</span>
###xml 844 846 <span type="species:ncbi:10273">MV</span>
###xml 881 886 <span type="species:ncbi:9606">human</span>
###xml 1027 1033 <span type="species:ncbi:9606">humans</span>
Although disruption of RIG-I signaling is conducive for MV replication in pHMs, high titers of MV progeny are not achieved because of premature death of MV-infected pHMs (data not shown). This appears to lend support to an emerging notion that the major function of pHMs in combating MV infection is to provide an altruistic source of TNF and type I IFN. It has been known for over a half-century that humans are highly resistant to MV infection, even following direct injections of live MV [1], but the molecular basis underlying the innate cellular restriction to MV infection in humans has never been elucidated. Thus, this novel RIG-I-coordinated signaling of TNF and type I IFN in leukocytes such as pHMs would provide some clues to explain how MV infection might be restricted in humans in vivo. In this regard, future clinical trials of MV as a new oncolytic virus to treat human cancers may provide a unique opportunity to determine the actual physiological relevance of leukocyte-based TNF and type I IFN responses in humans at the whole organism level.
###end p 50
###begin p 51
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Baud1">[52]</xref>
###xml 378 385 378 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 385 389 385 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Honda1">[36]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Sato1">[37]</xref>
Like IFN, TNF can also cause significant harm to the host when over-expressed [52]. Thus, a tight control over both TNF and type I IFN induction and shut-off is a key to homeostasis. Here, we show that IRF3 activation alone triggered only a transient upregulation of TNF and type I IFN. In most cell types, IRF3 is constitutively expressed, whereas IRF7 must usually be induced de novo[36],[37]. Thus, the sequential involvement of IRF3 and IRF7 in the early and later phase of TNF production allows us to postulate that, if the early phase production of TNF and type I IFN is sufficient to block viral infection, then the later phase production of both cytokines will be coordinately curtailed. Taken collectively, sustaining TNF induction through IRF3 and IRF7 thus provides the host with a fine-tuned regulatory mechanism to allow for only needed TNF expression in parallel with type I IFN. In particular, the identification of IRF7 as a key regulator for sustained production of both TNF and type I IFN may offer useful clues for designing new therapeutic strategies for disorders in which over-expression of either cytokine is suspected as a major culprit.
###end p 51
###begin p 52
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Kang1">[53]</xref>
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
Of relevance, recent work shows that in lipopolysaccharide-stimulated mouse macrophages, TLR4 interacts initially with MyD88 to mediate the early phase TNF expression and then with the newly induced 4-1BBL to sustain longer term TNF production [53]. Thus, sustained induction of TNF may be an intrinsic feature that can take place through distinct signaling pathways in a stimulus-specific fashion.
###end p 52
###begin p 53
###xml 95 102 95 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 434 438 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Honda1">[36]</xref>
###xml 439 443 435 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Lu1">[44]</xref>
###xml 444 448 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Marie1">[45]</xref>
###xml 33 35 <span type="species:ncbi:10273">MV</span>
###xml 148 150 <span type="species:ncbi:10273">MV</span>
###xml 503 505 <span type="species:ncbi:10273">MV</span>
###xml 683 685 <span type="species:ncbi:10273">MV</span>
###xml 908 910 <span type="species:ncbi:10273">MV</span>
A pivotal step in sustaining the MV-elicited co-induction of TNF and type I IFN in pHMs is the de novo synthesis of IRF7. Our ChIP data reveal that MV-stimulated MAVS signaling caused the direct binding of both IRF3 and IRF7 to the ISRE and IRFE sites in the IRF7 promoter, and that this is unaffected by STAT1 or NF-kappaB p65 knockdown. Notably, previous studies show that type I IFN and TNF each potently stimulate IRF7 expression [36],[44],[45]. In this study, we observed that, in addition to TNF, MV infection co-induced type I IFN in pHMs. We further observed that IRF7 was strongly induced in pHMs by either exogenous type I IFN or TNF (data not shown), thus indicating that MV-elicited type I IFN and TNF also likely contribute to IRF7 upregulation in pHMs. Taken together, these data suggest that IFN-STAT1, TNF-NF-kappaB and MAVS-IRF3/IRF7 signaling cascades are mobilized independently following MV infection to induce IRF7 expression in pHMs. Because the protein synthesis of both type I IFN and TNF requires that IRF3/IRF7 be activated first, the direct binding of virally activated IRF3 and IRF7 to the ISRE and IRFE in the IRF7 promoter thus provides a rapid shortcut to trigger IRF7 transcription, whereby an initial weak signal serves as the positive feedforward/feedback platform for a strong IRF7 expression at the later times through robust secondary response pathways of IFN-STAT1 and TNF-NF-kappaB.
###end p 53
###begin p 54
###xml 187 192 <span type="species:ncbi:9606">human</span>
###xml 402 407 <span type="species:ncbi:9606">human</span>
In summary, our study shows that RIG-I sensing of a DNA poxvirus infection in pHMs is critically linked to co-regulated TNF and type I IFN responses that control viral tropism in primary human cells in general. These data indicate that cytoplasmic RNA sensors may play a more important role than previously envisaged in triggering the innate antiviral cellular defenses against DNA virus infections in human cells.
###end p 54
###begin title 55
Materials and Methods
###end title 55
###begin title 56
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human fibroblasts, macrophages and lymphocytes
###end title 56
###begin p 57
###xml 1034 1038 1026 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Gupta1">[54]</xref>
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 200 205 <span type="species:ncbi:9606">human</span>
###xml 219 224 <span type="species:ncbi:9606">human</span>
###xml 806 811 <span type="species:ncbi:9606">human</span>
###xml 828 830 <span type="species:ncbi:10273">MV</span>
###xml 945 950 <span type="species:ncbi:9606">human</span>
Primary human skin fibroblasts CCD-922Sk (kindly provided by Dr. Scot Roberts) were maintained in MEM with 10% FBS, penicillin (100 u/ml) and streptomycin (100 microg/ml). To prepare pHMs and primary human lymphocytes, human peripheral blood mononuclear cells were first obtained by density gradient centrifugation over HISTOPAQUE-1077 (Sigma) according to the product instruction. Subsequently, the isolated peripheral blood mononuclear cells were suspended in RPMI 1640 supplemented with 5% FBS, penicillin (100 u/ml) and streptomycin (100 microg/ml) and were allowed to adhere to plastic plates for 1 h. The adherent monocytes were then separated from the nonadherent lymphocytes by repeated washing with plain medium. The monocyte-depleted nonadherent leukocyte fractions were collected as the primary human lymphocytes for MV infection experiments whereas the adherent mononcytes were cultured in RPMI 1640 supplemented with 10% autologous human serum for 7 days to allow differentiation into macrophages as described previously [54].
###end p 57
###begin title 58
###xml 0 2 <span type="species:ncbi:10273">MV</span>
###xml 19 21 <span type="species:ncbi:10273">MV</span>
MV and recombinant MV-hTNF
###end title 58
###begin p 59
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lacZ</italic>
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Mossman1">[55]</xref>
###xml 507 513 507 513 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GGTACC</named-content>
###xml 507 513 507 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><named-content content-type="gene">GGTACC</named-content></italic>
###xml 513 532 513 532 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">ATACGACGTCGTACGCGAA</named-content>
###xml 532 540 532 540 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TCTG GCA</named-content>
###xml 575 596 575 596 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AAGATCTAAGTCGACCCCGGG</named-content>
###xml 575 596 575 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><named-content content-type="gene">AAGATCTAAGTCGACCCCGGG</named-content></italic>
###xml 596 629 596 629 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TAATGAA TTCTACGTAGCGGCCGCAAGCTAGC</named-content>
###xml 596 629 596 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><named-content content-type="gene">TAATGAA TTCTACGTAGCGGCCGCAAGCTAGC</named-content></italic>
###xml 629 646 629 646 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TCTTTATTAAACTCGTA</named-content>
###xml 646 656 646 656 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">ATAGCGAGGA</named-content>
###xml 742 748 742 748 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GAGCTC</named-content>
###xml 742 748 742 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><named-content content-type="gene">GAGCTC</named-content></italic>
###xml 748 775 748 775 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TAGTATACAGCGATACGTCAATGGACA</named-content>
###xml 789 829 789 829 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGCTAGCTTGCGGCCGCTACGTAGAATTCATTACCCGGGG</named-content>
###xml 789 829 789 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><named-content content-type="gene">AGCTAGCTTGCGGCCGCTACGTAGAATTCATTACCCGGGG</named-content></italic>
###xml 829 842 829 842 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TCGACTTAGATCT</named-content>
###xml 829 842 829 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><named-content content-type="gene">TCGACTTAGATCT</named-content></italic>
###xml 842 867 842 867 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AACCGGTGATCGATCCATTATAGGA</named-content>
###xml 1262 1265 1262 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gpt</italic>
###xml 1358 1362 1358 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</italic>
###xml 1414 1418 1414 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Chakrabarti1">[56]</xref>
###xml 1422 1426 1422 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFP</italic>
###xml 1437 1440 1437 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF</italic>
###xml 1655 1659 1655 1659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Falkner1">[57]</xref>
###xml 1768 1772 1768 1772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Mossman1">[55]</xref>
###xml 0 2 <span type="species:ncbi:10273">MV</span>
###xml 166 168 <span type="species:ncbi:10273">MV</span>
###xml 227 229 <span type="species:ncbi:10273">MV</span>
###xml 409 411 <span type="species:ncbi:10273">MV</span>
###xml 447 449 <span type="species:ncbi:10273">MV</span>
###xml 1281 1295 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 1431 1436 <span type="species:ncbi:9606">human</span>
###xml 1678 1680 <span type="species:ncbi:10273">MV</span>
###xml 1812 1814 <span type="species:ncbi:10273">MV</span>
###xml 1909 1911 <span type="species:ncbi:10273">MV</span>
###xml 1915 1917 <span type="species:ncbi:10273">MV</span>
###xml 1979 1984 <span type="species:ncbi:9606">human</span>
MV (Lausanne strain) with lacZ gene inserted at an innocuous intergenic site under the control of a late viral promoter was described previously [55]. UV-inactivated MV was prepared with a Stratagene Stratalinker. To construct MV-hTNF, using vMyxlac as the parental virus, we first conducted PCR synthesis of flanking sequences for homologous recombination. The left flanking sequence (FL) for insertion into MV ORF M131R, a nonessential gene for MV replication, was synthesized with primer pair: FLF_KpnI: GGTACCATACGACGTCGTACGCGAATCTG GCA and FLR_MCS (multi-cloning site): AAGATCTAAGTCGACCCCGGGTAATGAA TTCTACGTAGCGGCCGCAAGCTAGCTCTTTATTAAACTCGTAATAGCGAGGA. The right flanking sequence (FR) was made similarly with the primer pair: FRR_SacI: GAGCTCTAGTATACAGCGATACGTCAATGGACA and FRF_MCS: AGCTAGCTTGCGGCCGCTACGTAGAATTCATTACCCGGGGTCGACTTAGATCTAACCGGTGATCGATCCATTATAGGA. Note that the above-italicized letters indicate MCS. Then, the FL and FR PCR products were mixed and ligated with a second round PCR using the primer pair FLF_KpnI and FRR_SacI. The flanking sequence containing the MCS was cloned into pBluescriptKS+ between KpnI and SacI, and the sequence fidelity was confirmed. The MCS contains RE sites: NheI, NotI, EcoRI, SmaI, SalI, and BglII. Next, the gpt gene driven by vaccinia virus early/late promoter p7.5 was inserted into the BglII site and EGFP driven by a synthetic poxvirus early/late promoter [56] or EGFP and human TNF, each controlled independently but in the opposite directions by synthetic poxvirus early/late promoters, were inserted between NheI and SmaI sites. Standard protocols for making recombination poxviruses were used [57]. The titration of MV-hTNF progeny virus was conducted on RK-13 using the standard plaque assay as described [55]. For confirmation of TNF expression by MV-hTNF, the whole cell lysates and supernatants from the RK-13 cells infected by either control MV or MV-hTNF were rendered for immunoblotting analysis using an anti-human TNF antibody.
###end p 59
###begin title 60
Virus infection, X-gal staining, beta-gal and viral yield assays
###end title 60
###begin p 61
###xml 299 302 293 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wang1">[3]</xref>
###xml 440 444 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Li1">[58]</xref>
###xml 450 451 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</italic>
###xml 736 740 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wong2">[59]</xref>
###xml 787 791 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Mossman1">[55]</xref>
###xml 0 2 <span type="species:ncbi:10273">MV</span>
###xml 252 254 <span type="species:ncbi:10273">MV</span>
###xml 384 386 <span type="species:ncbi:10273">MV</span>
###xml 684 688 <span type="species:ncbi:12104?1.0">EMCV</span>
###xml 747 749 <span type="species:ncbi:10273">MV</span>
MV was used at an MOI of 0.0l for X-gal staining and beta-gal assay and at an MOI of 1.0 for RT-PCR, immunoblotting, ELISA and ChIP experiments. X-gal staining with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (Sigma) was performed to visualize MV blue foci 48 h after infection as described [3]. Microscopic images of X-gal staining were taken with a Leica DMIRE2 microscope. MV beta-gal assay was performed as previously described [58] with o-nitrophenyl-beta-D-galactopyranoside (Sigma) 48 h after infection. The beta-gal activity was normalized as optical density at 420 nm per milligram of total cellular protein. For viral yield assays at 48 h after infection, titers of EMCV infection samples were determined on BHK cells [59] while MV titers were determined on BGMK cells [55] in terms of plaque-forming units per ml (pfu/ml) using the standard plaque assay.
###end p 61
###begin title 62
Cytokine treatments, primary antibodies, immunoblotting, ELISA and neutralization experiments
###end title 62
###begin p 63
###xml 796 799 776 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Wang1">[3]</xref>
###xml 884 888 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Perry1">[60]</xref>
###xml 1410 1414 1387 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Lokensgard1">[61]</xref>
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 269 271 <span type="species:ncbi:10273">MV</span>
###xml 275 279 <span type="species:ncbi:12104?1.0">EMCV</span>
###xml 512 517 <span type="species:ncbi:9606">human</span>
###xml 531 536 <span type="species:ncbi:9606">human</span>
###xml 1250 1252 <span type="species:ncbi:10273">MV</span>
###xml 1502 1507 <span type="species:ncbi:9606">human</span>
###xml 1545 1550 <span type="species:ncbi:9606">human</span>
###xml 1631 1636 <span type="species:ncbi:9606">human</span>
###xml 1650 1655 <span type="species:ncbi:9606">human</span>
###xml 1735 1737 <span type="species:ncbi:10273">MV</span>
Recombinant human IFN-beta and TNF were from PBL Biomedical Laboratories and Biosource International, respectively. IFN-beta was used at 150 units/ml while TNF was used at 10 ng/ml. Two cytokines were either added alone or together to the media when the infection with MV or EMCV was started and maintained throughout the entire treatment period. The primary antibodies were obtained from the following suppliers: anti-IRF3, anti-IRF7, anti-NF-kappaB p65 and anti-USF2 antibodies, Santa Cruz Biotechnology; anti-human TNF and anti-human IFN-alpha/beta antibodies, Biosource International; anti-beta-actin antibody, Sigma; anti-STAT1 antibody, Transduction Laboratories. For immunoblotting, whole cell extracts were prepared at each specified time after various treatments as previously described [3]. The preparation of nuclear extracts was done according to the published procedures [60]. The extracted proteins were resolved on 7.5-12% SDS-PAGE and transferred to Hybond-C nitrocellulose (Amersham Pharmacia Biotech). Immunoblotting was performed with respective primary antibodies, and bands were visualized with secondary HRP-conjugated antibodies and ECL system (NEN Life Science Products). To quantitate TNF and IFN-beta, the supernatants from MV-infected cell cultures were collected at various time points as specified after treatments and subjected to analysis by standard sandwich ELISA as described [61]. For the neutralization of TNF or IFN-alpha/beta, or both TNF and IFN-alpha/beta, anti-human TNF antibody (20 microg/ml), or anti-human IFN-alpha/beta antibodies (each at 1,000 neutralization units/ml), or both anti-human TNF and anti-human IFN-alpha/beta antibodies were added, respectively, to the medium 2 h prior to MV infection of pHMs as indicated and kept throughout the entire infection period.
###end p 63
###begin title 64
Transfection of siRNAs and poly(I:C)
###end title 64
###begin p 65
###xml 298 319 298 319 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CAGAAGAUCUUGAGGAUAAUU</named-content>
###xml 332 358 332 358 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-P.UUAUCCUCAAGAUCUUCUGUU</named-content>
###xml 387 408 387 408 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCACAGAAGUGUAUAUUGGUU</named-content>
###xml 421 447 421 447 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-P.CCAAUAUACACUUCUGUGCUU</named-content>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 449 454 <span type="species:ncbi:9606">Human</span>
The siRNA oligonucleotides targeting human RIG-I (NM_014314), MDA5 (NM_022168), MAVS (VISA, NM_020746), IRF3 (NM_001571) and IRF7 (NM_001572) as well as control siRNA siCONTROL #1 were obtained from DHARMACON. The two individual pairs of RIG-I siRNA sequences are as follows: RIG-I siRNA-1: sense, CAGAAGAUCUUGAGGAUAAUU, antisense, 5'-P.UUAUCCUCAAGAUCUUCUGUU), and RIG-I siRNA-2: sense, GCACAGAAGUGUAUAUUGGUU, antisense, 5'-P.CCAAUAUACACUUCUGUGCUU. Human NF-kappaB p65 and STAT1 siRNAs were obtained from Cell Signaling Technology. siRNAs were transfected into pHMs using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer's specifications. At 48 or 72 h after the transfection of various siRNAs as indicated, the cells were used for further experiments. Synthetic dsRNA polyinosinic-polycytidylic (poly(I:C)) was from Sigma. For transfection, cells were incubated for various times as indicated with 1.5 microg/ml of poly(I:C) complexed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
###end p 65
###begin title 66
Immunofluorescence microscopy
###end title 66
###begin p 67
###xml 84 86 <span type="species:ncbi:10273">MV</span>
###xml 210 214 <span type="species:ncbi:9925">goat</span>
###xml 235 241 <span type="species:ncbi:9986">rabbit</span>
###xml 373 377 <span type="species:ncbi:9925">goat</span>
###xml 383 389 <span type="species:ncbi:9986">rabbit</span>
For immunofluorescent staining, pHMs were grown on coverslips. After infection with MV for the indicated times, the infected cells were fixed in cold methanol for 10 min, washed in PBS and blocked in 5% normal goat serum for 50 min. A rabbit anti-IRF3 antibody was then applied at room temperature for 1 h followed by a 45-min secondary detection with Texas Red-conjugated goat anti-rabbit IgG. Thereafter, the nuclear DNA of the immunolabeled cells were counterstained with DAPI (4',6-diamidino-2-phenylindole, dihydrochloride, Molecular Probes) according to the product specification. The secondary antibody conjugate was from Jackson ImmunoResearch Laboratories. The fluorescence images were taken with a Leica DMIRE2 microscope.
###end p 67
###begin title 68
RT-PCR and chromatin immunoprecipitation assay
###end title 68
###begin p 69
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Stewart1">[62]</xref>
###xml 259 263 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Benedict2">[63]</xref>
###xml 286 290 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Sasai1">[64]</xref>
###xml 224 229 <span type="species:ncbi:9606">human</span>
After various treatments as indicated, total RNA was isolated using a RNeasy kit (Qiagen). Reverse transcription was performed using Superscript reverse transcriptase (Invitrogen). RT-PCR conditions and primer sequences for human TNF and GAPDH [62], IFN-beta [63], RIG-I, MDA5 and MAVS [64] were described.
###end p 69
###begin p 70
###xml 49 53 49 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Ning1">[43]</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000099-Ning1">[43]</xref>
###xml 88 90 <span type="species:ncbi:10273">MV</span>
###xml 239 245 <span type="species:ncbi:9986">rabbit</span>
ChIP assay was conducted as described previously [43]. Briefly, pHMs were infected with MV for 12 h and then subjected to cross-linking by formaldehyde. Immunoprecipitation was performed with the specific antibodies or a control antibody (rabbit IgG) as indicated. After reversion of the protein-DNA cross-links in the immunopreciptitates, the purified DNA was analyzed by PCR for the sequences that contain ISRE and IRFE in the endogenous IRF7 promoter. PCR conditions and the specific primers for IRF7 ISRE and IRFE were described [43].
###end p 70
###begin title 71
Supporting Information
###end title 71
###begin p 72
###xml 177 198 177 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 62 64 <span type="species:ncbi:10273">MV</span>
###xml 85 87 <span type="species:ncbi:10273">MV</span>
###xml 107 109 <span type="species:ncbi:10273">MV</span>
###xml 223 225 <span type="species:ncbi:10273">MV</span>
###xml 242 244 <span type="species:ncbi:10273">MV</span>
###xml 299 301 <span type="species:ncbi:10273">MV</span>
###xml 305 307 <span type="species:ncbi:10273">MV</span>
###xml 446 451 <span type="species:ncbi:9606">human</span>
Confirmation of insertion and expression of human TNF gene in MV genome. (A) Control MV DNA or recombinant MV-hTNF DNA was extracted and analyzed with PCR pairs as specified in Materials and Methods. Lanes 1 and 2: control MV. Lanes 3 and 4: MV-hTNF. (B) RK-13 cells were infected by either control MV or MV-hTNF as indicated for 24 h. The whole cell lysates and supernatants were collected and rendered for immunoblotting analysis using an anti-human TNF antibody.
###end p 72
###begin p 73
(0.90 MB TIF)
###end p 73
###begin p 74
Click here for additional data file.
###end p 74
###begin p 75
###xml 78 83 <span type="species:ncbi:9606">human</span>
###xml 380 382 <span type="species:ncbi:10273">MV</span>
Two pairs of RIG-I siRNA oligos share similar silencing phenotypes in primary human macrophages. (A) pHMs were transfected with control siRNA or RIG-I siRNA-1 or RIG-I siRNA-2 as indicated (top panel). The cells were analyzed 48 h later by RT-PCR for RIG-I mRNA levels. GAPDH was used as control. (B, C) pHMs or various siRNA pHMs as indicated were mock-infected or infected with MV for 24 h and the accumulation of TNF and IFN-beta in the culture supernatants was assessed by ELISA. Data in (B) and (C) represent mean +/- SD.
###end p 75
###begin p 76
(0.77 MB TIF)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
RIG-I siRNA transfection does not activate nonspecific type I IFN response in pHMs. (A) pHMs were mock transfected or transfected with poly(I:C) or with RIG-I siRNA-1 or RIG-I siRNA-2 for 24 h. IFN-beta accumulation in the culture supernatants was assessed by ELISA. Data represent mean +/- SD. (B) pHMs were mock transfected or transfected with poly(I:C) or with RIG-I siRNA-1 or RIG-I siRNA-2 for 12 h. Total RNA was analyzed by RT-PCR for induction of IFN-beta mRNA. GAPDH was used as control.
###end p 78
###begin p 79
(0.70 MB TIF)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
###xml 73 77 <span type="species:ncbi:12104?1.0">EMCV</span>
We thank S. Roberts for CCD-922Sk cells, R. Dowling and N. Sonenberg for EMCV and J. Hiscott for IRF3 regents, which helped in the development of this project. We are grateful to I. Moniz for her administrative assistance at the Robarts Research Institute.
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
###xml 20 32 <span type="species:ncbi:10273">myxoma virus</span>
Immune responses to myxoma virus.
###end article-title 83
###begin article-title 84
###xml 67 79 <span type="species:ncbi:10273">myxoma virus</span>
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier.
###end article-title 84
###begin article-title 85
Principles of Virology.
###end article-title 85
###begin article-title 86
Pathogen recognition and innate immunity.
###end article-title 86
###begin article-title 87
Innate immune recognition.
###end article-title 87
###begin article-title 88
TLR signaling.
###end article-title 88
###begin article-title 89
When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA.
###end article-title 89
###begin article-title 90
Function of RIG-I-like receptors in antiviral innate immunity.
###end article-title 90
###begin article-title 91
5'-Triphosphate RNA is the ligand for RIG-I.
###end article-title 91
###begin article-title 92
RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates.
###end article-title 92
###begin article-title 93
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.
###end article-title 93
###begin article-title 94
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.
###end article-title 94
###begin article-title 95
CARD games between virus and host get a new player.
###end article-title 95
###begin article-title 96
Molecular pathways in virus-induced cytokine production.
###end article-title 96
###begin article-title 97
Viruses and the TNF-related cytokines, an evolving battle.
###end article-title 97
###begin article-title 98
Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis.
###end article-title 98
###begin article-title 99
Type I interferons in host defense.
###end article-title 99
###begin article-title 100
Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses.
###end article-title 100
###begin article-title 101
###xml 0 12 <span type="species:ncbi:10273">Myxoma virus</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.
###end article-title 101
###begin article-title 102
###xml 10 15 <span type="species:ncbi:9606">human</span>
###xml 60 72 <span type="species:ncbi:10273">myxoma virus</span>
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.
###end article-title 102
###begin article-title 103
###xml 34 60 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 65 77 <span type="species:ncbi:10273">myxoma virus</span>
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.
###end article-title 103
###begin article-title 104
Antiviral actions of interferons.
###end article-title 104
###begin article-title 105
Antiviral properties of TNF.
###end article-title 105
###begin article-title 106
Tumor necrosis factor, other cytokines and disease.
###end article-title 106
###begin article-title 107
Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter.
###end article-title 107
###begin article-title 108
###xml 0 14 <span type="species:ncbi:10245">Vaccinia virus</span>
Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation.
###end article-title 108
###begin article-title 109
Hemin-activated macrophages home to the pancreas and protect from acute pancreatitis via heme oxygenase-1 induction.
###end article-title 109
###begin article-title 110
Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system.
###end article-title 110
###begin article-title 111
Induction of the interferon response by siRNA is cell type- and duplex length-dependent.
###end article-title 111
###begin article-title 112
Activation of the interferon system by short-interfering RNAs.
###end article-title 112
###begin article-title 113
Antiviral innate immunity pathways.
###end article-title 113
###begin article-title 114
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.
###end article-title 114
###begin article-title 115
###xml 79 96 <span type="species:ncbi:11103">hepatitis C virus</span>
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.
###end article-title 115
###begin article-title 116
VISA is an adapter protein required for virus-triggered IFN-beta signaling.
###end article-title 116
###begin article-title 117
IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.
###end article-title 117
###begin article-title 118
Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction.
###end article-title 118
###begin article-title 119
Achieving stability of lipopolysaccharide-induced NF-kappaB activation.
###end article-title 119
###begin article-title 120
Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity.
###end article-title 120
###begin article-title 121
In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.
###end article-title 121
###begin article-title 122
Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator.
###end article-title 122
###begin article-title 123
Overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function.
###end article-title 123
###begin article-title 124
Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling.
###end article-title 124
###begin article-title 125
Stimulation of IRF-7 gene expression by tumor necrosis factor alpha: requirement for NFkappa B transcription factor and gene accessibility.
###end article-title 125
###begin article-title 126
Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7.
###end article-title 126
###begin article-title 127
Essential role of IPS-1 in innate immune responses against RNA viruses.
###end article-title 127
###begin article-title 128
###xml 91 96 <span type="species:ncbi:9606">human</span>
Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells.
###end article-title 128
###begin article-title 129
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus.
###end article-title 129
###begin article-title 130
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response.
###end article-title 130
###begin article-title 131
Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules.
###end article-title 131
###begin article-title 132
###xml 0 12 <span type="species:ncbi:10273">Myxoma virus</span>
###xml 34 39 <span type="species:ncbi:9606">human</span>
Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses.
###end article-title 132
###begin article-title 133
Signal transduction by tumor necrosis factor and its relatives.
###end article-title 133
###begin article-title 134
Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages.
###end article-title 134
###begin article-title 135
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 88 99 <span type="species:ncbi:205488">ebola virus</span>
Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro.
###end article-title 135
###begin article-title 136
###xml 0 12 <span type="species:ncbi:10273">Myxoma virus</span>
###xml 141 157 <span type="species:ncbi:9986">European rabbits</span>
Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits.
###end article-title 136
###begin article-title 137
###xml 20 34 <span type="species:ncbi:10245">vaccinia virus</span>
Compact, synthetic, vaccinia virus early/late promoter for protein expression.
###end article-title 137
###begin article-title 138
###xml 0 16 <span type="species:ncbi:562">Escherichia coli</span>
###xml 58 72 <span type="species:ncbi:10245">vaccinia virus</span>
Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors.
###end article-title 138
###begin article-title 139
Transient, nonlethal expression of genes in vertebrate cells by recombinant entomopoxviruses.
###end article-title 139
###begin article-title 140
Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons.
###end article-title 140
###begin article-title 141
Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection.
###end article-title 141
###begin article-title 142
###xml 63 68 <span type="species:ncbi:9606">human</span>
Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus.
###end article-title 142
###begin article-title 143
###xml 55 58 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 118 123 <span type="species:ncbi:9606">human</span>
c-Jun N-terminal kinase negatively regulates dsRNA and RSV induction of tumor necrosis factor- alpha transcription in human epithelial cells.
###end article-title 143
###begin article-title 144
Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus detente.
###end article-title 144
###begin article-title 145
NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction.
###end article-title 145
###begin p 146
The authors have declared that no competing interests exist.
###end p 146
###begin p 147
GM holds a Howard Hughes Medical Institute International Scholarship. Supported by the Canadian Institutes of Health Research.
###end p 147

